| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch + Lomb Corporation - BLCO |
NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Bausch + Lomb Corporation("Bausch + Lomb" or the "Company") (NYSE:BLCO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-05-16 13:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch + Lomb Corporation - BLCO |
NEW YORK CITY, NY / ACCESS Newswire / May 14, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Bausch + Lomb Corporation("Bausch + Lomb" or the "Company") (NYSE:BLCO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-05-14 13:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch + Lomb Corporation - BLCO |
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Bausch + Lomb Corporation (“Bausch + Lomb” or the “Company”) (NYSE: BLCO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. |
globenewswire.com |
2025-05-13 16:17:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch + Lomb Corporation - BLCO |
NEW YORK , May 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bausch + Lomb Corporation ("Bausch + Lomb" or the "Company") (NYSE: BLCO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2025-05-12 21:07:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch + Lomb Corporation - BLCO |
NEW YORK, NY / ACCESS Newswire / May 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Bausch + Lomb Corporation("Bausch + Lomb" or the "Company") (NYSE:BLCO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-05-10 12:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch + Lomb Corporation - BLCO |
NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Bausch + Lomb Corporation (“Bausch + Lomb” or the “Company”) (NYSE: BLCO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
globenewswire.com |
2025-05-09 12:00:00 |
Czytaj oryginał (ang.) |
| Securities Fraud Investigation Into Bausch + Lomb Corporation (BLCO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm |
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Bausch + Lomb Corporation (“BLCO” or the “Company”) (NYSE: BLCO) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON BAUSCH + LOMB CORPORATION (BLCO), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened?. |
businesswire.com |
2025-05-08 22:15:00 |
Czytaj oryginał (ang.) |
| Bausch + Lomb Corporation (BLCO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation |
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Bausch + Lomb Corporation (“BLCO” or the “Company”) (NYSE: BLCO) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN BAUSCH + LOMB CORPORATION (BLCO), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal righ. |
businesswire.com |
2025-05-08 20:13:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch + Lomb Corporation - BLCO |
NEW YORK CITY, NY / ACCESS Newswire / May 8, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Bausch + Lomb Corporation("Bausch + Lomb" or the "Company") (NYSE:BLCO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-05-08 12:00:00 |
Czytaj oryginał (ang.) |
| Securities Fraud Investigation Into Bausch + Lomb Corporation (BLCO) Announced – Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz |
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Bausch + Lomb Corporation (“BLCO” or the “Company”) (NYSE: BLCO) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON BAUSCH + LOMB CORPORATION (BLCO), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is the Investigation About? On March 27, 2025, BLCO disclosed that it had “[begun] to. |
businesswire.com |
2025-05-08 02:05:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch + Lomb Corporation - BLCO |
NEW YORK CITY, NY / ACCESS Newswire / May 7, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Bausch + Lomb Corporation("Bausch + Lomb" or the "Company") (NYSE:BLCO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-05-07 12:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch + Lomb Corporation - BLCO |
NEW YORK , May 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bausch + Lomb Corporation ("Bausch + Lomb" or the "Company") (NYSE: BLCO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2025-05-06 18:04:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch + Lomb Corporation - BLCO |
NEW YORK, NY / ACCESS Newswire / May 3, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Bausch + Lomb Corporation ("Bausch + Lomb" or the "Company") (NYSE:BLCO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-05-03 14:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch + Lomb Corporation - BLCO |
NEW YORK, NY / ACCESS Newswire / May 2, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Bausch + Lomb Corporation ("Bausch + Lomb" or the "Company") (NYSE:BLCO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-05-02 14:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch + Lomb Corporation - BLCO |
NEW YORK CITY, NY / ACCESS Newswire / May 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Bausch + Lomb Corporation ("Bausch + Lomb" or the "Company") (NYSE:BLCO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-05-01 15:30:00 |
Czytaj oryginał (ang.) |
| Bausch + Lomb Corporation (BLCO) Q1 2025 Earnings Call Transcript |
Bausch + Lomb Corporation (NYSE:BLCO ) Q1 2025 Earnings Conference Call April 30, 2025 8:00 AM ET Company Participants George Gadkowski - Vice President, Investor Relations & Business Insights Brent Saunders - Chairman & Chief Executive Officer Sam Eldessouky - Chief Financial Officer Yehia Hashad - Head, R&D Conference Call Participants Patrick Wood - Morgan Stanley Young Li - Jefferies Joanne Wuensch - Citibank Douglas Miehm - RBC Capital Matt Miksic - Barclays Robbie Marcus - JPMorgan Operator Good morning, and welcome to Bausch + Lomb's First Quarter 2025 Earnings Call. All participants will be in listen-only mode. |
seekingalpha.com |
2025-04-30 15:02:34 |
Czytaj oryginał (ang.) |
| Bausch + Lomb (BLCO) Reports Q1 Earnings: What Key Metrics Have to Say |
While the top- and bottom-line numbers for Bausch + Lomb (BLCO) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2025-04-30 14:36:03 |
Czytaj oryginał (ang.) |
| Bausch + Lomb (BLCO) Reports Q1 Loss, Misses Revenue Estimates |
Bausch + Lomb (BLCO) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of $0.03. This compares to earnings of $0.07 per share a year ago. |
zacks.com |
2025-04-30 13:10:49 |
Czytaj oryginał (ang.) |
| Bausch + Lomb Returning enVista® Intraocular Lenses to Market Following Voluntary Recall |
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced it has identified the event that led to its recent voluntary recall of intraocular lenses (IOLs) on the enVista platform. Now that the cause and affected lots have been confirmed, the company will return these models to market. “We voluntarily recalled these lenses because patient safety dictates every decision. |
businesswire.com |
2025-04-24 11:00:00 |
Czytaj oryginał (ang.) |
| BLCO or DHR: Which Is the Better Value Stock Right Now? |
Investors interested in stocks from the Medical Services sector have probably already heard of Bausch + Lomb (BLCO) and Danaher (DHR). But which of these two stocks presents investors with the better value opportunity right now? |
zacks.com |
2025-04-23 16:40:38 |
Czytaj oryginał (ang.) |
| Bausch + Lomb Corporation (BLCO) Q4 2024 Earnings Call Transcript |
Bausch + Lomb Corporation (NYSE:BLCO ) Q4 2024 Results Conference Call February 19, 2025 8:00 AM ET Company Participants George Gadkowski - Vice President of Investor Relations Brent Saunders - CEO & Chairman Sam Eldessouky - Executive VP & CFO Yehia Hashad - Head of R&D and Chief Medical Officer Conference Call Participants Patrick Wood - Morgan Stanley Joanne Wuensch - Citibank Craig Bijou - Bank of America Larry Biegelsen - Wells Fargo Robbie Marcus - JPMorgan Denis Reznik - Raymond James Operator Greetings. Welcome to the Bausch + Lomb Fourth Quarter 2024 Earnings Call. |
seekingalpha.com |
2025-02-19 14:19:03 |
Czytaj oryginał (ang.) |
| Bausch + Lomb (BLCO) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates |
While the top- and bottom-line numbers for Bausch + Lomb (BLCO) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2025-02-19 12:35:33 |
Czytaj oryginał (ang.) |
| Bausch & Lomb to shake up contact lenses with deal off the table |
Bausch & Lomb said this month it had explored taking the company private with a third-party buyer. No deal was reached as a consortium of private equity firms TPG and Blackstone reportedly backed out. |
youtube.com |
2025-02-19 11:16:41 |
Czytaj oryginał (ang.) |
| Bausch + Lomb (BLCO) Surpasses Q4 Earnings and Revenue Estimates |
Bausch + Lomb (BLCO) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.24 per share a year ago. |
zacks.com |
2025-02-19 11:05:26 |
Czytaj oryginał (ang.) |
| Unlocking Q4 Potential of Bausch + Lomb (BLCO): Exploring Wall Street Estimates for Key Metrics |
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Bausch + Lomb (BLCO), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024. |
zacks.com |
2025-02-17 12:21:08 |
Czytaj oryginał (ang.) |
| Bausch Health Provides Update on Strategic Alternatives |
LAVAL, QC / ACCESS Newswire / February 6, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, issued the following update on a potential sale of its subsidiary, Bausch + Lomb Corporation (NYSE:BLCO)(TSX:BLCO), which was disclosed in December 2024 following a regulatory request: "In the second half of 2024, Bausch Health engaged with its financial advisors to work on various liability management alternatives. At the same time, Bausch + Lomb was approached by a private equity firm with an indication of interest for a potential sale of Bausch + Lomb at a compelling valuation. |
accessnewswire.com |
2025-02-06 09:05:00 |
Czytaj oryginał (ang.) |
| Bausch and Lomb CEO: Right on track with our important initiatives |
Brent Saunders, Bausch and Lomb CEO, joins 'Money Movers' to discuss how Saunders has changed the portfolio in his time as chief executive, what the growth is like for Bausch and Lomb, and much more. |
youtube.com |
2025-01-14 14:24:00 |
Czytaj oryginał (ang.) |
| Bausch + Lomb Corporation (BLCO) Q3 2024 Earnings Call Transcript |
Bausch + Lomb Corporation (NYSE:BLCO ) Q3 2024 Results Conference Call October 30, 2024 8:00 AM ET Company Participants George Gadkowski - Vice President of Investor Relations and Business Insights Brenton Saunders - CEO & Chairman Osama Eldessouky - Executive VP & CFO Conference Call Participants Patrick Wood - Morgan Stanley Xuyang Li - Jefferies Matt Miksic - Barclays Doug Miehm - RBC Capital Markets Lilia-Celine Lozada - JPMorgan Operator Good morning and welcome to Bausch + Lomb's Third Quarter 2024 Earnings Call. [Operator Instructions] Please note this event is being recorded. |
seekingalpha.com |
2024-10-30 17:12:11 |
Czytaj oryginał (ang.) |
| Bausch + Lomb (BLCO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates |
The headline numbers for Bausch + Lomb (BLCO) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2024-10-30 12:36:03 |
Czytaj oryginał (ang.) |
| Bausch + Lomb (BLCO) Q3 Earnings and Revenues Top Estimates |
Bausch + Lomb (BLCO) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.22 per share a year ago. |
zacks.com |
2024-10-30 11:16:17 |
Czytaj oryginał (ang.) |
| Why Bausch + Lomb Stock Soared by Over 7% on Monday |
It was quite a busy and eventful day for the company. |
fool.com |
2024-10-14 22:40:26 |
Czytaj oryginał (ang.) |
| Bausch + Lomb Stock Pops as TPG, Blackstone Consider Joint Bid |
Bausch + Lomb Corporation (BLCO) shares popped Monday morning following reports Blackstone (BX) and TPG (TPG) are considering teaming up to buy the eyecare company. |
investopedia.com |
2024-10-14 16:20:48 |
Czytaj oryginał (ang.) |
| Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio? |
This week, the Federal Reserve's decision to reduce interest rates by 50 basis points boosted share prices across the technology, construction, industrial, machinery, and financial sectors. |
benzinga.com |
2024-09-22 21:34:03 |
Czytaj oryginał (ang.) |
| Bausch + Lomb (BLCO) Surges 14.5%: Is This an Indication of Further Gains? |
Bausch + Lomb (BLCO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
zacks.com |
2024-09-17 09:16:18 |
Czytaj oryginał (ang.) |
| Why Bausch + Lomb Rallied Today |
The Financial Times reported Bausch + Lomb is in talks with advisors to potentially sell itself. It had formerly sought to spin off from parent Bausch Health in a stock-for-stock deal. |
fool.com |
2024-09-16 19:31:31 |
Czytaj oryginał (ang.) |
| Bausch + Lomb Stock Jumps Amid Reports Of A Sale |
Bausch + Lomb (BLCO) shares popped Monday following a report that the eyecare company is considering a sale. |
investopedia.com |
2024-09-16 17:16:18 |
Czytaj oryginał (ang.) |
| Bausch Reportedly Explores A Sale; Could Alcon, J&J Or AbbVie Buy It? |
Bausch + Lomb stock surged Monday — briefly breaking out — on a report the company is working with advisors to explore a potential sale. |
investors.com |
2024-09-16 15:38:31 |
Czytaj oryginał (ang.) |
| Bausch & Lomb reportedly exploring sale, shares rise |
Bausch & Lomb stock surged on reports the American-Canadian eye health products firm is exploring a sale as it seeks to resolve issues related to its separation from its debt-laden parent company Bausch Health Cos Inc (NYSE:BHC). According to a Financial Times report citing people familiar with the matter, Bausch & Lomb is working with Goldman Sachs to gauge interest from potential buyers. |
proactiveinvestors.com |
2024-09-16 14:40:56 |
Czytaj oryginał (ang.) |
| Bausch + Lomb Corporation (BLCO) Q2 2024 Earnings Call Transcript |
Bausch + Lomb Corporation (NYSE:BLCO ) Q2 2024 Earnings Call July 31, 2024 8:00 AM ET Company Participants George Gadkowski - Vice President, Investor Relations Brent Saunders - Chairman and Chief Executive Officer Sam Eldessouky - Chief Financial Officer Conference Call Participants Xuyang Li - Jefferies Patrick Wood - Morgan Stanley Craig Bijou - Bank of America Robbie Marcus - JPMorgan Douglas Miehm - RBC Capital Markets Matt Miksic - Barclays Operator Good morning, and welcome to Bausch + Lomb's Second Quarter 2024 Earnings Call. [Operator Instructions] Please note, this event is being recorded. |
seekingalpha.com |
2024-07-31 20:42:07 |
Czytaj oryginał (ang.) |
| Bausch + Lomb (BLCO) Reports Q2 Earnings: What Key Metrics Have to Say |
While the top- and bottom-line numbers for Bausch + Lomb (BLCO) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2024-07-31 14:36:44 |
Czytaj oryginał (ang.) |
| Bausch + Lomb (BLCO) Matches Q2 Earnings Estimates |
Bausch + Lomb (BLCO) came out with quarterly earnings of $0.13 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.18 per share a year ago. |
zacks.com |
2024-07-31 13:21:11 |
Czytaj oryginał (ang.) |
| Analysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out for |
Bausch + Lomb (BLCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-07-24 15:07:44 |
Czytaj oryginał (ang.) |
| Bausch + Lomb Announces Presentation of New Data at the European Dry Eye Society 2024 Congress |
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of several scientific presentations and educational events during the European Dry Eye Society (EuDEC) 2024 Congress, which will take place in Madrid, Spain, June 20-22. Data presentations highlight the results of several studies evaluating consumer, pharmaceutical and vision care products from. |
businesswire.com |
2024-06-17 11:00:00 |
Czytaj oryginał (ang.) |
| Bausch + Lomb INFUSE® for Astigmatism Silicone Hydrogel Daily Disposable Contact Lenses Introduced in the United States |
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. introduction of Bausch + Lomb INFUSE for Astigmatism daily disposable contact lenses. Engineered with a next-generation lens material infused with ProBalance Technology™ and the company's proprietary OpticAlign® design, INFUSE for Astigmatism provides astigmatic patients clear, stable vision, all-day co. |
businesswire.com |
2024-06-10 11:00:00 |
Czytaj oryginał (ang.) |
| Bausch + Lomb Launches Blink™ NutriTears® Clinically Proven Nutritional Supplement for Dry Eyes in the United States |
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Blink NutriTears, a clinically proven over-the-counter supplement that targets the key root causes of dry eyes, promotes healthy tear production and provides noticeable relief of eye dryness symptoms in as little as two to four weeks.1,2* “We offer dry eye sufferers a wide array of options tha. |
businesswire.com |
2024-06-03 11:00:00 |
Czytaj oryginał (ang.) |
| Bausch + Lomb Announces 2024 Annual Meeting of Shareholder Results |
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2024 annual meeting of shareholders (the “Annual Meeting”) held on May 29, 2024. The detailed results of the vote for the election of directors are set out below: Name For Against Broker Non-Votes Nathalie Bernier 344,550,519 28. |
businesswire.com |
2024-05-29 20:30:00 |
Czytaj oryginał (ang.) |
| Bausch + Lomb Receives Health Canada Approval for enVista® Envy™* Full Visual Range Intraocular Lens |
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Health Canada has approved the enVista® Envy™* full visual range intraocular lens (IOL). This is the first global regulatory approval of the new lens, which offers a full range of vision with excellent dysphotopsia tolerance on the widely used enVista IOL platform. “enVista Envy is the next step in the dram. |
businesswire.com |
2024-05-28 10:59:00 |
Czytaj oryginał (ang.) |